Nintedanib is a receptor tyrosine kinase inhibitor targeting VEGF, PDGF, FGF, and TGF-β receptors, and it has been shown that when nintedanib is administered at doses between 1 and 4 μM, it inhibits cell proliferation, induces GO/G1 phase block, inhibits migration and invasion of keloid fibroblasts, and significantly inhibits the expression of type I and type III collagen in keloid fibroblasts (112). The gene discussed is VEGFA; the disease is keloid.